Skip to main content

ESTALIS 250/50 norethindrone acetate and estradiol 250/50 mcg/day transdermal therapeutic system (Canada)

Section 19A approved medicine
ESTALIS 250/50 norethindrone acetate and estradiol 250/50 mcg/day transdermal therapeutic system (Canada)
Section 19A approval holder
Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Phone
1300 788 261
Approved until
Status
Current
Medicines in short supply/unavailable
ESTALIS CONTINUOUS 50/250 estradiol 50mcg/day norethisterone acetate 250mcg/day patch sachet - ARTG 70817
Indication(s)

For the short-term treatment of symptoms of estrogen deficiency in menopausal women who have an intact uterus.

Images
Picture of Estalis 250-50 transdermal therapeutic system Canada - label

Help us improve the Therapeutic Goods Administration site